Phase II Iressa Versus Vinorelbine (INVITE)

Sponsor
AstraZeneca
Study ID
NCT00256711
Phase
PHASE2
Status
Completed

Conditions

  • Non-Small-Cell Lung Carcinoma

Eligibility Criteria

Sex
ALL
Age
70 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a randomized, open label, parallel group, multi-centre, phase II study of progression free survival, comparing oral ZD1839 (IRESSA™) (250 mg tablet once daily) to vinorelbine 30 mg/m2 infusion on days 1 and 8 of a 21-day cycle) in chemonaïve, elderly patients with locally advanced (stage IIIB) or metastatic (stage IV) non-small cell lung cancer.

Key Dates

Start date
Jul 31, 2004
Status verified
Apr 2009
Completion
Feb 28, 2006

Study Design

Enrollment
192 participants
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Primary Outcome Measure

To compare ZD1839 and vinorelbine in terms of progression free survival

Related Studies